ArticleAntimicrobial agents and chemotherapy2021
Open access · greenAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 61 citations in OpenAlex.
- L2 β-lactamase contributes to ceftolozane-tazobactam resistance inAntimicrobial agents and chemotherapy · 2026Article
- Variable phage susceptibility ofbioRxiv : the preprint server for biology · 2026Article
- Beyond Resistance Genes:Life (Basel, Switzerland) · 2026Review
- Ceftazidime-avibactam resistance evolution inAntimicrobial agents and chemotherapy · 2026Article
- Landscape of resistance to ceftolozane/tazobactam and ceftazidime/avibactam in strains of Pseudomonas aeruginosa: a genomic approach in strains without selection pressure in a tertiary-care paediatric hospital in Mexico.BMC infectious diseases · 2026Article
- A novel mechanism of ceftolozane-tazobactam resistance inbioRxiv : the preprint server for biology · 2026Article
- Evaluation of Phenotypic and Genotypic Susceptibility Testing Methods for Newer β-lactam/β-lactamase Inhibitor Combinations in Multidrug Resistant Pseudomonas aeruginosa.The Journal of infectious diseases · 2026Article
- Current and future options for the treatment of serious infections due to carbapenem-resistantClinical microbiology reviews · 2025Review
- Effectiveness of imipenem-relebactam for multidrug-resistantAntimicrobial agents and chemotherapy · 2025Observational
- Deciphering the emergence of mutations in Pseudomonas aeruginosa after ceftolozane/tazobactam treatment and evaluating therapeutic alternatives.BMC microbiology · 2025Article
- Clinical Analysis ofJournal of clinical medicine · 2025Article
- Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?Antimicrobial agents and chemotherapy · 2025Article
- Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Modern antiseptics against multidrug-resistantFrontiers in microbiology · 2025Article
- Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study.BMC infectious diseases · 2024Article
- Article
- In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol.The Journal of antibiotics · 2024Article
- Clinical outcomes and emergence of resistance ofAntimicrobial agents and chemotherapy · 2024Article
- ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics.Nature reviews. Microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Abigail M RubioDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Ellen G KlineDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Chelsea E JonesDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Liang ChenHackensack-Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Barry N KreiswirthHackensack-Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
M Hong NguyenDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Cornelius J ClancyDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Vaughn S CooperDepartment of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-7726-0765
Ghady HaidarDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0003-0634-8211
Daria Van TyneDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-7284-0103
Ryan K ShieldsDepartment of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA shieldsrk@upmc.edu.ORCID 0000-0001-9794-5665
University of Pittsburgh · USHackensack Meridian Health · US
Funding
Institutional Career Development CoreKL2TR001856 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RAY, KRISTIN N, RUBIO, DORIS M · 2016 to 2025
$13.8MPredicting the emergence of antibiotic resistance through multi-omics approaches and Immune System-surveillanU01AI124302 · NIAID · BOSTON COLLEGE · PI BENTO, JOSE, COOPER, VAUGHN · 2016 to 2020
$10.2MThe molecular basis of the epidemic blaKPC gene KlebsiellaR01AI090155 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI KREISWIRTH, BARRY NEAL · 2011 to 2021
$7.2MThe Gut Microbiome in Carbapenem-Resistant Enterobacteriaceae Colonization, Persistence, Infection, and Tolerance after Lung or Liver TransplantationK23AI154546 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HAIDAR, GHADY · 2021 to 2025
$896kCaspofungin pharmacokinetics-pharmacodynamics during intra-adbominal candidiasisK08AI114883 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIELDS, RYAN K · 2015 to 2019
$858kUse of site-specific pharmacokinetics to optimize antibiotic combinations and prevent the emergence of resistance against CRER21AI151363 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIELDS, RYAN K · 2021 to 2022
$431kCharacterization and suppression of resistance to new CRE agentsR03AI144636 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIELDS, RYAN K · 2019 to 2020
$157kNCATS NIH HHS KL2 TR001856NIAID NIH HHS K08 AI114883NIAID NIH HHS K23 AI154546NIAID NIH HHS R01 AI090155NIAID NIH HHS R03 AI144636NIAID NIH HHS R21 AI151363NIAID NIH HHS U01 AI124302
Abstract
We compared the
Indexed as
Pseudomonas aeruginosaPseudomonas InfectionsAnti-Bacterial AgentsCephalosporinsDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsTazobactamAnti-Bacterial AgentsceftolozaneCephalosporinsTazobactamantibiotic resistanceceftolozane-tazobactamimipenem-relebactamPseudomonas aeruginosa
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.